PARAGON-HF: Sacubitril/Valsartan vs Valsartan in Patients With and Without Diabetes and Heart Failure With Preserved Ejection Fraction

April 2-4, 2022; Washington, DC
In patients with HFpEF, sacubitril/valsartan attenuated the rate of decline in renal outcomes similarly in patients with and without diabetes compared to valsartan alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: April 6, 2022


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Expert commentary on management and challenges when treating patients with anemia of CKD, from Clinical Care Options (CCO)

person default Ajay Singh, MBBS, FRCP, MBA Released: November 28, 2022

Unlocked downloadable slides featuring experts insight on the management of patients with obesity from Clinical Care Options (CCO).

Caroline Apovian, MD Ken Fujioka, MD Released: November 2, 2022

Concise microlearning module featuring expert insight on the cardiorenal benefits of SGLT2 inhibitors in T2D from Clinical Care Options (CCO)

Jennifer B. Green, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: July 12, 2022 Expired: July 11, 2023

Unlocked downloadable slides featuring an overview of the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: July 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings